See also this year's filing and all EDGAR filings for this company.
PDF Report 0001124105_2023_GYRE_THERAPEUTICS_INC.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.08911222780569514, 'aggregate_val': 9753000, 'exp_sum': 8955000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 17366000, 'ResearchAndDevelopmentExpense': 13037000, 'remainder_Expenses': -21448000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001124105, GYRE THERAPEUTICS INC.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 28,206,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 4,000 |
| 3 | remainder_Assets | 234,000 |
| 4 | LiabilitiesCurrent | 16,824,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 17,366,000 |
| 9 | ResearchAndDevelopmentExpense | 13,037,000 |
| 10 | remainder_Expenses | -20,650,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 717,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 28,444,000 |
| 1 | Liabilities | 16,824,000 |
| 2 | Expenses | 9,753,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 11,620,000 |
| 5 | NetIncome | -9,036,000 |
| 6 | ComprehensiveNetIncome | -9,036,000 |
| 7 | BaseVar | 27,869,000 |
| 8 | EconomicCapitalRatio | 0.484 |
Edgar->Model Mapping
Feature Distribution
Change over Time
